Global Information Lookup Global Information

Recombinant factor VIIa information


Recombinant factor VIIa
INN: Eptacog alfa
Clinical data
Trade namesNovoseven, Sevenfact, others
Other namesrFVIIa, Coagulation factor VIIa (recombinant), Coagulation factor VIIa (recombinant)-jncw
BiosimilarsAryoseven
AHFS/Drugs.comMonograph
License data
  • US DailyMed: Coagulation factor VIIa (recombinant)
Pregnancy
category
  • AU: B1
Routes of
administration
Intravenous injection
ATC code
  • B02BD08 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[1]
  • US: ℞-only[2][3]
  • EU: Rx-only[4][5]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
  • 102786-61-8 checkY
DrugBank
  • DB00036
ChemSpider
  • none
UNII
  • AC71R787OV
KEGG
  • D00172

Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology.[4][5] It is administered via an injection into a vein.[6][4][5] It is used to treat bleeding episodes in people who have acquired haemophilia, among other indications.[7] There are several disimilar forms, and biosimilars for each. All forms are activated.

List of recombinant factor VIIa formulations
INN USAN Brand name Notes
Eptacog alfa (activated) coagulation factor VIIa (recombinant) Novoseven Oldest formulation, Baby hamster kidney cells (BHK).[7]
Eptacog alfa (activated) coagulation factor VIIa (recombinant) Novoseven RT Approved in the US in 2008.[2] BHK cells.[2]
Eptacog beta (activated) coagulation factor VIIa (recombinant)-jncw Sevenfact (US), Cevenfacta (EU) Biosimilar, produced through rabbit milk.[8] Approved in the EU in 2022.[5]

The most common side effects with Novoseven include venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment.[4] The most common side effects with Cevenfacta include injection site discomfort and hematoma (a collection of blood under the skin) as well as injection-related reactions, an increase in body temperature, dizziness and headache.[5]

Novoseven was approved for medical use in the European Union in February 1996,[4] and in the United States in March 1999.[9]

  1. ^ "NovoSeven 1 mg (50KIU) powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 21 November 2019. Archived from the original on 15 January 2021. Retrieved 1 April 2020.
  2. ^ a b c Cite error: The named reference NovoSeven RT FDA label was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Sevenfact FDA label was invoked but never defined (see the help page).
  4. ^ a b c d e "NovoSeven EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 27 February 2023.
  5. ^ a b c d e Cite error: The named reference Cevenfacta EPAR was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference FDA NovoSeven RT was invoked but never defined (see the help page).
  7. ^ a b Cite error: The named reference NovoSeven FDA label was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference FDA Sevenfact PR was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference FDA NovoSeven was invoked but never defined (see the help page).

and 23 Related for: Recombinant factor VIIa information

Request time (Page generated in 0.8714 seconds.)

Recombinant factor VIIa

Last Update:

Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. It is administered via an injection...

Word Count : 1756

Coagulation factor VII

Last Update:

factor VII), which in turn activates factor IX and factor X. Using genetic recombination a recombinant factor VIIa (eptacog alfa) (trade names include...

Word Count : 1386

Abdominal pregnancy

Last Update:

kind of pregnancy, with others even using tranexamic acid and recombinant factor VIIa, which both minimize blood loss. Generally, unless the placenta...

Word Count : 2859

Factor IX

Last Update:

peptide, glycosylated and then cleaved by factor XIa (of the contact pathway) or factor VIIa (of the tissue factor pathway) to produce a two-chain form, where...

Word Count : 1926

Peptic ulcer disease

Last Update:

plasma (FFP), vitamin K, prothrombin complex concentrates, or recombinant factor VIIa can be given to reverse the effect of warfarin. High doses of vitamin...

Word Count : 5859

Major trauma

Last Update:

trauma. For severe bleeding, for example from bleeding disorders, recombinant factor VIIa—a protein that assists blood clotting—may be appropriate. While...

Word Count : 6624

Anticoagulant

Last Update:

recombinant factor VIIa, and prothrombin complex concentrate (PCC) have been utilized with proven efficacy. Specifically with warfarin, four factor PCC...

Word Count : 8837

Emergency bleeding control

Last Update:

trials to understand more about the potential benefits and risks. Recombinant factor VIIa (rFVIIa) is not, as of 2012, supported by the evidence for most...

Word Count : 2322

Warfarin

Last Update:

time (INR) every one to four weeks. Many other medications and dietary factors can interact with warfarin, either increasing or decreasing its effectiveness...

Word Count : 9737

Tissue factor

Last Update:

serine protease factor VIIa. The best known function of tissue factor is its role in blood coagulation. The complex of TF with factor VIIa catalyzes the...

Word Count : 1820

Acute liver failure

Last Update:

of whether there is poor nutritional status. Administration of recombinant factor VIIa has shown promise; however, this treatment approach requires further...

Word Count : 4266

Acquired haemophilia

Last Update:

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2:1700-1708...

Word Count : 1468

Thromboelastometry

Last Update:

hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost. 2004;2:102-10. Karger R, Egbring R, Weippert-Kretschmer...

Word Count : 2428

Coagulation

Last Update:

fresh frozen plasma are commonly used coagulation factor products. Recombinant activated human factor VII is increasingly popular in the treatment of major...

Word Count : 5909

Jeanne Lusher

Last Update:

1980s. Lusher later conducted the first studies on the use of recombinant factor VIIa in the treatment of bleeding episodes in patients with hemophilia...

Word Count : 1906

Disseminated intravascular coagulation

Last Update:

activated factor VIIa (normally present in trace amounts in the blood), forming the extrinsic tenase complex. This complex further activates factor IX and...

Word Count : 2402

Intracerebral hemorrhage

Last Update:

between intensive and less intensive blood pressure control. Giving Factor VIIa within 4 hours limits the bleeding and formation of a hematoma. However...

Word Count : 4483

Amniotic fluid embolism

Last Update:

promptly to prevent further complications. In the case of DIC, recombinant activated factor VIIa is quick way to address this issue. Serine proteinase inhibitor...

Word Count : 1947

Antithrombin

Last Update:

Factor II (thrombin) (IIa), and also the activated form of Factor VII (VIIa) from the tissue factor pathway (formerly known as the extrinsic pathway). The...

Word Count : 5331

Maxygen

Last Update:

2008, the company sold its MAXY-VII candidate drug, a recombinant form of clotting factor VIIa, to Bayer HealthCare. 2009 saw the formation of a joint...

Word Count : 880

Discovery and development of direct Xa inhibitors

Last Update:

slow, tight-binding inhibitor of factor Xa with a Ki value of 0.3–0.6 nM but it also inhibits trypsin. Recombinant Antistasin can be produced by genetically...

Word Count : 4916

Plateletpheresis

Last Update:

of transfusions may be reduced if these patients are given recombinant human factor VIIa[medical citation needed] since the underlying cause are antibodies...

Word Count : 3124

Cangene

Last Update:

development and commercialization of three drug candidates, recombinant blood clotting factors VIIa, VIII and IX, the latter of which is in clinical trials...

Word Count : 885

PDF Search Engine © AllGlobal.net